Literature DB >> 10442417

Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an International Surveillance Programme. SENTRY Participants Group.

M E Jones1, F J Schmitz, A C Fluit, J Acar, R Gupta, J Verhoef.   

Abstract

The SENTRY Antimicrobial Surveillance Programme was established to provide a coordinated, standardised, international surveillance on antimicrobial resistance. In one part of the programme, isolates from skin and soft tissue infections sent from 20 hospitals in 12 different European countries were investigated in the European coordinating centre. Of 1013 isolates, Staphylococcus aureus and Pseudomonas aeruginosa were the most significant species, constituting almost 50% of the referred isolates. Methicillin resistance in Staphylococcus aureus averaged 22% across Europe, only slightly less than that in isolates derived from blood. Less than 5% of the enterococcal isolates were resistant to vancomycin. Piperacillin/tazobactam was the most active penicillin-derived beta-lactam compound against Pseudomonas aeruginosa, inhibiting 91.3% of the isolates, while ceftazidime and cefepime were the most active cephalosporins, inhibiting 85.8% and 80.3% of the isolates, respectively. Putative extended-spectrum beta-lactamase production was not detected in Escherichia coli and was found in only 5.1% of the Klebsiella pneumoniae isolates. In general, strains of the family Enterobacteriaceae remained mostly susceptible to carbapenems, cefepime, and amikacin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10442417     DOI: 10.1007/s100960050308

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

1.  Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.

Authors:  Johannes Breedt; Jüri Teras; Janis Gardovskis; Frans Jacobus Maritz; Tiit Vaasna; Douglas Patrick Ross; Martine Gioud-Paquet; Nathalie Dartois; Evelyn J Ellis-Grosse; Evan Loh
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

2.  Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study.

Authors:  A C Fluit; C L Wielders; J Verhoef; F J Schmitz
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

Review 3.  Children hospitalized with skin and soft tissue infections: a guide to antibacterial selection and treatment.

Authors:  Joseph V Vayalumkal; Tajdin Jadavji
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

4.  Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.

Authors:  D L Stevens; L G Smith; J B Bruss; M A McConnell-Martin; S E Duvall; W M Todd; B Hafkin
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 5.  Staphylococcal skin infections in children: rational drug therapy recommendations.

Authors:  Shamez Ladhani; Mehdi Garbash
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 6.  A practical guide to the treatment of complicated skin and soft tissue infections.

Authors:  Horatio B Fung; Joanne Y Chang; Stephen Kuczynski
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Change in Antimicrobial Susceptibility of Skin-Colonizing Staphylococcus aureus in Korean Patients with Atopic Dermatitis during Ten-Year Period.

Authors:  Jung-Min Park; Ju-Hyun Jo; Hyunju Jin; Hyun-Chang Ko; Moon-Bum Kim; Jung-Min Kim; Do-Won Kim; Ho-Sun Jang; Byung-Soo Kim
Journal:  Ann Dermatol       Date:  2016-07-26       Impact factor: 1.444

9.  Meropenem in the treatment of complicated skin and soft tissue infections.

Authors:  Douglas N Fish
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.